Chembio Diagnostics (CEMI) Upgraded by Zacks Investment Research to Hold

Chembio Diagnostics stock has undergone multiple analysts rating changes in the recent past.  Chembio Diagnostics Upgraded by Zacks Investment Research on 10-11-21. In a note to investors, the firm issued a new rating of Hold. The analysts previously had rating of Sell.

Shares of Chembio Diagnostics traded down -$0.01 on Monday, reaching $2.37. 589363 shares of the stock traded hands, compared to its average volume of 3672304. Shares of Chembio Diagnostics were trading at $2.37 on Monday. The firm’s 50 day moving average is $2.68 and its 200 day moving average is $3.89.Chembio Diagnostics has a 12 month low of $2.35 and a 12 month high of $8.75. While on yearly highs and lows, Chembio Diagnostics’s today has traded high as $2.41 and has touched $2.35 on the downward trend. See More Analyst Rating at: RATING

Chembio Diagnostics Earnings and What to expect: 

Chembio Diagnostics last announced its earnings results on August 5th, 2021. The reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.38) by $0.07. The firm earned $6.46 million during the quarter. Chembio Diagnostics has generated ($1.28) earnings per share over the last year (($1.30) diluted earnings per share). Earnings for Chembio Diagnostics are expected to decrease in the coming year, from ($0.92) to ($0.99) per share. Chembio Diagnostics has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Thursday, November 4th, 2021 based off prior year’s report dates.

Earnings for Chembio Diagnostics are expected to decrease in the coming year, from ($0.92) to ($0.99) per share. The P/E ratio of Chembio Diagnostics is -1.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Chembio Diagnostics is -1.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Chembio Diagnostics has a P/B Ratio of 1.72. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Chembio Diagnostics (CEMI) Moving Average Technical Analysis

5 day Moving Average is $2.40 And 5 day price change is -$0.02 (-0.84%)  with average volume for 5 day average is 724,600. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $2.53 and 20 day price change is -$0.29 (-10.90%) and average 20 day moving volume is 1,656,635. 50 day moving average is $2.68  and 50 day price change is -$0.47 ( -16.55%)  and with average volume for 50 days is : 4,981,782. 200 day moving average is $3.89  and 200 day price change is -$2.89 (-54.94%)  and with average volume for 200 days is : 6,223,849.

Other owners latest trading in Chembio Diagnostics :

  • On 9/7/2021 shares held by Newbridge Financial Services Group Inc. were 74,500 which equates to market value of $0.22M and appx 0.10% owners of Chembio Diagnostics
  • On 9/3/2021 shares held by Parametric Portfolio Associates LLC were 13,298 which equates to market value of $39K and appx 0.00% owners of Chembio Diagnostics
  • On 8/25/2021 shares held by Marshall Wace LLP were 10,977 which equates to market value of $33K and appx 0.00% owners of Chembio Diagnostics
  • In total Institutional ownership equates to Institutional Ownership Percentage: 16.68% for Chembio Diagnostics

See More Analyst Rating at: RATING